IMI2 1st call for proposals 2014

With regards to Type 1 diabetes, the aims to bring together leading clinicians and researchers from the areas of immunology, beta cell biology, and biomarker research from academia and industry. Participants should focus on providing an improved molecular understanding of the T1DM patients, delivering insights into the disease heterogeneity and providing tools for the identification of high-risk patients - with a view to create a foundation for personalised therapy of T1DM patients.

For retinal diseases, on the other hand, the aim is to evaluate novel endpoint candidates for dry AMD (Age-Related Macular Degeneration) and DR (Diabetic retinopathy). The evaluation should cover the technical, medical and health economic appropriateness of a method and bridge preclinical and clinical studies.

The data generated is expected to serve as a basis for initial discussion with regulatory agencies and/or HTA-bodies towards the acceptance of the resulting outcomes as endpoints for future clinical programmes.

Official call announcements - participant portal